SCHEMBL25254136

SCHEMBL25254136

COc1cc(C=O)c(Br)c2ccccc12

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKDC P78527 2/20 0.53
ALDH1A1 P00352 6/20 0.48
KDM4E B2RXH2 2/20 0.48
TSHR P16473 1/20 0.48
TDP1 Q9NUW8 1/20 0.48
MCL1 Q07820 1/20 0.45
ERN1 O75460 8/20 0.44
TLR2 O60603 1/20 0.42
TLR1 Q15399 1/20 0.42
TLR6 Q9Y2C9 1/20 0.42
LMNA P02545 2/20 0.40
MAPT P10636 2/20 0.40
HPGD P15428 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
CYP3A4 P08684 1/20 0.40
ALOX15 P16050 1/20 0.40
HSD17B10 Q99714 1/20 0.40
NPC1 O15118 1/20 0.40
POLB P06746 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5950414 0.81 ALDH1A1 (0.50) PRKDCALDH1A1KDM4ETSHRTDP1
SCHEMBL1506977 0.81 MCL1 (0.58) PRKDCALDH1A1KDM4ETSHRTDP1
SCHEMBL31346762 0.81 MCL1 (0.58) PRKDCALDH1A1KDM4ETSHRTDP1
SCHEMBL13894553 0.81 ALDH1A1 (0.50) PRKDCALDH1A1KDM4ETSHRTDP1
SCHEMBL24101486 0.79 ERN1 (0.58) ERN1TLR2TLR1TLR6
SCHEMBL8078047 0.77 GAA (0.50) ALDH1A1TDP1LMNAMAPTHPGD
SCHEMBL8202688 0.76 NQO1 (0.47) ALDH1A1KDM4ELMNAMAPTHPGD
SCHEMBL545661 0.74 MAPT (0.54) ALDH1A1KDM4ETSHRTDP1MCL1
SCHEMBL8849630 0.74 IDO1 (0.42) ALDH1A1KDM4ELMNAMAPTHPGD
SCHEMBL29708066 0.74 MAPT (0.54) ALDH1A1KDM4ETSHRTDP1MCL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12570613-B2 Imidazoquinoline or benzoindazolone compound and intermediate for preparing same LMITO THERAPEUTICS INC. (KR) 2026-03-10 US disclosed
US-20240034719-A1 IMIDAZOQUINOLINE OR BENZOINDAZOLONE COMPOUND AND INTERMEDIATE FOR PREPARING SAME LMITO THERAPEUTICS INC. (KR) 2024-02-01 US disclosed
EP-4212530-A1 IMIDAZOLQUINOLINE OR BENZOINDAZOLONE COMPOUND AND INTERMEDIATE FOR PREPARING SAME Lmito Therapeutics Inc. (KR) 2023-07-19 EP disclosed
CN-115956071-A Imidazoquinoline or benzindazolone compounds and intermediates for their preparation LMITO药业株式会社 2023-04-11 CN disclosed
WO-2022039460-A1 IMIDAZOLQUINOLINE OR BENZOINDAZOLONE COMPOUND AND INTERMEDIATE FOR PREPARING SAME 주식회사 엘마이토테라퓨틱스 2022-02-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240034719-A1 IMIDAZOQUINOLINE OR BENZOINDAZOLONE COMPOUND AND INTERMEDIATE FOR PREPARING SAME NQO1, NFE2L2, KEAP1 PRKDC 2530/4885ALDH1A1 122/4885KDM4E 4102/4885
US-12570613-B2 Imidazoquinoline or benzoindazolone compound and intermediate for preparing same NQO1, CBR1, NFE2L2 PRKDC 3791/4885ALDH1A1 238/4885KDM4E 4043/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.